What is the pulmonary fibrosis treatment market size in 2026?

The global pulmonary fibrosis treatment market is projected to reach US$3.7 billion in 2026.

What drives the pulmonary fibrosis treatment market?

The pulmonary fibrosis treatment market is driven by an aging population, rising diagnoses of IPF and PPF, expanding regulatory approvals, and adoption of new antifibrotic therapies.

What is the growth rate for the pulmonary fibrosis treatment market?

The pulmonary fibrosis treatment market is poised to witness a CAGR of 6.2% from 2026 to 2033.

What are the key market opportunities?

Key opportunities include expansion of PPF treatments, development of novel antifibrotic mechanisms, inhaled drug delivery, and broader access to therapies through generic competition and healthcare expansion.

Who are the key players in the pulmonary fibrosis treatment market?

Some of the key market players include Boehringer Ingelheim, F. Hoffmann-La Roche, Genentech, United Therapeutics, and Cipla.

Table of Content - Pulmonary Fibrosis Treatment Market Size, Share, and Growth Forecast, 2026

Executive Summary
1. Global Pulmonary Fibrosis Treatment Market Snapshot, 2026 and 2033
2. Market Opportunity Assessment, 2026 – 2033, US$ Bn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Key Trends
3. Macro-economic Factors
  1. Global Sectoral Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors – Relevance and Impact
Value Added Insights
1. Tool Adoption Analysis
2. Regulatory Landscape
3. Value Chain Analysis
4. PESTLE Analysis
5. Porter’s Five Force Analysis
Price Analysis, 2025A
1. Key Highlights
2. Key Factors Impacting Deployment Costs
3. Pricing Analysis, By Drug Type
Global Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
  1. Market Volume (Units) Projections
  2. Market Size (US$ Bn) and Y-o-Y Growth
  3. Absolute $ Opportunity
2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
  1. Historical Market Size (US$ Bn) Analysis, 2020-2025
  2. Current Market Size (US$ Bn) Analysis and Forecast, 2026 – 2033
3. Global Pulmonary Fibrosis Treatment Market Outlook: Drug Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Drug Type, 2020 – 2025
  3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
    1. Pirfenidone
    2. Nintedanib
    3. Others
  4. Market Attractiveness Analysis: Drug Type
4. Global Pulmonary Fibrosis Treatment Market Outlook: Route of Administration
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2020 – 2025
  3. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
    1. Oral
    2. Injectable
  4. Market Attractiveness Analysis: Route of Administration
5. Global Pulmonary Fibrosis Treatment Market Outlook: Indication
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Indication, 2020 – 2025
  3. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026 – 2033
    1. Idiopathic Pulmonary Fibrosis (IPF)
    2. Progressive Pulmonary Fibrosis (PPF)
    3. Others
    4. Market Attractiveness Analysis: Indication
Global Pulmonary Fibrosis Treatment Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2020 – 2025
3. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2026 – 2033
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 – 2025
  1. By Country
  2. By Drug Type
  3. By Route of Administration
  4. By Indication
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
  1. U.S.
  2. Canada
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
  1. Pirfenidone
  2. Nintedanib
  3. Others
5. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
  1. Oral
  2. Injectable
6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026-2033
  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Progressive Pulmonary Fibrosis (PPF)
  3. Others
  4. Market Attractiveness Analysis
Europe Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 – 2025
  1. By Country
  2. By Drug Type
  3. By Route of Administration
  4. By Indication
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
  1. Pirfenidone
  2. Nintedanib
  3. Others
5. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
  1. Oral
  2. Injectable
6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026-2033
  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Progressive Pulmonary Fibrosis (PPF)
  3. Others
7. Market Attractiveness Analysis
East Asia Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 – 2025
  1. By Country
  2. By Drug Type
  3. By Route of Administration
  4. By Indication
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
  1. China
  2. Japan
  3. South Korea
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
  1. Pirfenidone
  2. Nintedanib
  3. Others
5. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
  1. Oral
  2. Injectable
6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026-2033
  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Progressive Pulmonary Fibrosis (PPF)
  3. Others
7. Market Attractiveness Analysis
South Asia & Oceania Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 – 2025
  1. By Country
  2. By Drug Type
  3. By Route of Administration
  4. By Indication
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
  1. Pirfenidone
  2. Nintedanib
  3. Others
5. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
  1. Oral
  2. Injectable
6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026-2033
  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Progressive Pulmonary Fibrosis (PPF)
  3. Others
7. Market Attractiveness Analysis
Latin America Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 – 2025
  1. By Country
  2. By Drug Type
  3. By Route of Administration
  4. By Indication
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
  1. Pirfenidone
  2. Nintedanib
  3. Others
5. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
  1. Oral
  2. Injectable
6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026-2033
  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Progressive Pulmonary Fibrosis (PPF)
  3. Others
7. Market Attractiveness Analysis
Middle East & Africa Pulmonary Fibrosis Treatment Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 – 2025
  1. By Country
  2. By Drug Type
  3. By Route of Administration
  4. By Indication
3. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2026 – 2033
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Current Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Drug Type, 2026 – 2033
  1. Pirfenidone
  2. Nintedanib
  3. Others
5. Current Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2026 – 2033
  1. Oral
  2. Injectable
6. Current Market Size (US$ Bn) Analysis and Forecast, By Indication, 2026-2033
  1. Idiopathic Pulmonary Fibrosis (IPF)
  2. Progressive Pulmonary Fibrosis (PPF)
  3. Others
7. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
  1. Boehringer Ingelheim
    1. Overview
    2. Segments and Deployments
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. F. Hoffmann-La Roche
  3. Genentech
  4. United Therapeutics
  5. Shionogi & Co.
  6. Cipla
  7. Teva Pharmaceuticals
  8. Accord Healthcare
  9. Amneal Pharmaceuticals
  10. Dr. Reddy’s Laboratories
  11. Sun Pharmaceutical Industries
  12. Lupin
  13. Torrent Pharmaceuticals
  14. Zydus Lifesciences
  15. Glenmark Pharmaceuticals
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Pulmonary Fibrosis Treatment Market Size, Share, and Growth Forecast, 2026 - 2033

Pulmonary Fibrosis Treatment Market by Drug Type (Pirfenidone, Nintedanib, Others), Route of Administration (Oral, Injectable), Indication (Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF), Others), and Regional Analysis for 2026 - 2033

Quick Links

Our Partners

Secure Payments Through